The client challenge
Some air-treatment products arrive at the lab as finished devices. Glow Guardian began as a functional candle concept. It was designed to burn while releasing active constituents into room air to reduce viable airborne microorganisms under controlled test conditions.1,2
The development question centered on where treatment would occur. A filter-based purifier pulls air through media, a ducted system treats air in an HVAC path, and an in-device treatment system acts inside a housing. Glow Guardian's active-in-air concept was intended to release constituents into room air where they could interact with airborne microorganisms.1
A routine pass/fail test would not answer all of Glow Guardian's development questions. The client needed a development pathway connecting formulation refinement with aerosol science, bioaerosol generation, viable sampling, chamber testing, and data interpretation.
ARE Labs as development partner
ARE Labs supported Glow Guardian through formulation support, chamber challenge testing, method adaptation, and final efficacy studies. The team evaluated a candle formulation, measured the bioaerosol response, then adjusted the formulation. That cycle repeated many times as the team worked toward a final product configuration.
For active-in-air products, mechanism and method fit matter. Small changes in formulation, release behavior, burn characteristics, particle behavior, or active delivery can affect performance. Repeated chamber challenges gave the team feedback during development, as well as data for the final report.
How the product was tested
The primary efficacy study tested the Glow Guardian air treatment candle against a broad range of respirable microorganisms in a sealed environmental bioaerosol test chamber. According to the source report, the protocol was modeled on FDA 510(k)-style in-room air purifier testing methods, and the work complied with Good Laboratory Practice expectations in 21 CFR Part 58.3
Each microorganism was aerosolized into a controlled chamber containing the candle. ARE Labs used controlled bioaerosol generation and viable sampling to track concentrations over time. The collected samples underwent serial dilution, plating, incubation, and enumeration to quantify viable bioaerosol concentrations. Control trials measured natural chamber decay. To calculate net reduction, ARE Labs subtracted the natural chamber decay measured in those control trials from the results of the candle trials.
| Organism or surrogate | Organism type | Maximum net percent reduction | Average CADR |
|---|---|---|---|
| MS2 bacteriophage | Unenveloped RNA virus surrogate | 99.74% | 35.40 cfm |
| Phi X bacteriophage | Unenveloped DNA virus surrogate | 99.15% | 24.05 cfm |
| Staphylococcus epidermidis | Gram-positive bacterium | 99.93% | 35.29 cfm |
| Listeria innocua | Gram-positive bacterium | 99.97% | 35.87 cfm |
| Klebsiella aerogenes | Gram-negative bacterium | 99.99% | 46.17 cfm |
| Pseudomonas syringae | Gram-negative bacterium | 99.78% | 47.32 cfm |
| Aspergillus brasiliensis | Mold spores | 81.84% | 12.23 cfm |
| Bacillus subtilis | Bacterial endospores | 34.84% | 3.53 cfm |
Broad-spectrum results
The final broad-range study showed measurable efficacy across all organism groups tested. For most non-spore organisms, the Glow Guardian candle achieved greater than 99% maximum net percent reduction over the two-hour chamber test period after control correction. Reductions were lower for more resistant organisms, including mold spores and bacterial endospores.
View figure data as a table
| organism | Maximum net reduction |
|---|---|
| MS2 | 99.74% |
| Phi X | 99.15% |
| S. epidermidis | 99.93% |
| L. innocua | 99.97% |
| K. aerogenes | 99.99% |
| P. syringae | 99.78% |
| A. brasiliensis | 81.84% |
| B. subtilis | 34.84% |
Source: client-approved ARE Labs broad-range bioaerosol efficacy report summary.
- Organism names are shortened in the chart labels for readability.
- Values are control-corrected maximum net percent reductions from the source article.
The reductions varied by organism. Gram-negative bacteria and virus surrogates showed high reductions, while mold spores and bacterial endospores were more resistant. That pattern is consistent with the greater environmental durability of mold spores and bacterial endospores.
The first-minute question
The active-in-air approach raised another question: what happens immediately after a bioaerosol enters a room that has already been pretreated? With filtration, in-device UV, and many recirculating air cleaners, contaminated air generally must reach the device or treatment zone. If active material is already distributed in room air, the early-event behavior may matter.
ARE Labs examined that question in a separate pretreatment study. The candle was lit before bioaerosol introduction. After a defined pretreatment period, organisms were aerosolized into the chamber, and viable concentrations were measured after one minute of chamber mixing.
| Pretreatment challenge organism | Organism type | Net percent reduction after one minute |
|---|---|---|
| MS2 bacteriophage | Unenveloped RNA virus surrogate | 90.66% |
| Klebsiella aerogenes | Gram-negative bacterium | 41.75% |
| Staphylococcus epidermidis | Gram-positive bacterium | 30.80% |
The pretreatment study is summarized here because it shaped the active-in-air method story.
Business impact
By the end of the program, Glow Guardian had advanced a functional candle formulation from concept toward product readiness. The client also had broad-range viable bioaerosol efficacy data, one-minute room-pretreatment data, and a public-facing science story supported by ARE Labs reports. ARE Labs had contributed to both the product's development and its testing.1
Buyers, partners, retailers, and investors need evidence behind a novel consumer-facing air-treatment product's claims. That means showing how its mechanism can be challenged, measured, and tested repeatedly, then explaining the results within the boundaries of the test data.1
The official record for U.S. Patent No. 12,467,016 B1, Air purification candle, names Jamie Balarashti as inventor and Glow Guardian, Inc. as assignee. That record and ARE Labs' development role provide context for the testing described here.2
What this says about method fit
Glow Guardian's development brought together aerosol generation, viable bioaerosol sampling, chamber design, particle characterization, formulation support, and study reporting. ARE Labs contributed across development and testing, selecting methods around the product mechanism.3
For aerosol and air-treatment developers, the testing plan needs to reflect how the product is meant to work. Products that depend on airborne actives, room-scale interaction, or nontraditional release behavior may need methods beyond the closest familiar test category. Otherwise, useful development signals can be missed or misread.
Summary
Glow Guardian needed more than final validation; the client needed help testing, interpreting results, and refining a novel active-in-air product concept throughout development. ARE Labs connected formulation iteration with room-scale bioaerosol challenge methods and control-corrected efficacy data. Those measurements supported the client's public product story, with claims kept within the limits of the test results.